Share Price:

APNASPENAspen Pharmacare Hldgs24101-177 (-0.73%)
Our Response to Covid
Country Sites

Aspen is in a closed period from 1st July 2024 until the publication of the FY2024 results on the JSE SENS platform to be released on the 3rd September 2024.

Author: Shauneen Beukes

Aspen’s Mandela Day programme changes more than 910 000 lives over 14 years

Durban – JSE Limited listed Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded pharmaceutical company, is celebrating its 14th consecutive year of Group-wide participation in Mandela Day.   Stephen Saad, Aspen Group Chief Executive said, “ Aspen has a track record of improving access to healthcare to all patients but more particularly the… Continue reading Aspen’s Mandela Day programme changes more than 910 000 lives over 14 years

Aspen backs Donald Ramphadi to bring home the gold in upcoming mobility impaired tennis championships

Donald Ramphadi and Stavros Nicolaou at the handover of his high performance wheelchair

Johannesburg, South Africa – Aspen Pharmacare Holdings Limited (“Aspen”), a global multinational specialty pharmaceutical company, has presented a state-of-the-art high performance wheelchair to South African wheelchair tennis star Donald Ramphadi.   Ramphadi, a French-open double quads champion and a prominent figure in wheelchair tennis, reached his maiden Grand Slam final at the Australian Open Wheelchair… Continue reading Aspen backs Donald Ramphadi to bring home the gold in upcoming mobility impaired tennis championships

Aspen announces additional pharmaceutical donations for Ukranian patients

(l-r): Ambassador and Plenipotentiary of Ukraine to South Africa H.E Liubov Abravitova; Stavros Nicolaou, Aspen Group Senior Executive Strategic Trade; Former President of Ukraine H.E Viktor Yushchenko; Former first Lady Mrs Kateryna Yushchenko.

  Johannesburg, South Africa – Aspen Pharmacare, Africa’s largest pharmaceutical company, has announced continued humanitarian support to Ukraine, confirming further donations of critical care products to treat hospitalized patients who have been impacted by the ongoing conflict in that country.   Stavros Nicolaou, Aspen Group Senior Executive Strategic Trade, said, “Aspen is highly sensitised to… Continue reading Aspen announces additional pharmaceutical donations for Ukranian patients

Aspen building momentum with revenue up 10% to R21,1 billion

Stephen Saad, Aspen Group Chief Executive

Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid unaudited interim Group financial results for the six months ended 31 December 2023. SALIENT HIGHLIGHTS Revenue increased by 10% (2% in constant exchange rate (“CER”)) to R21,1 billion (December 2022: R19,2 billion) Normalised EBITDA increased by 2% (-5%… Continue reading Aspen building momentum with revenue up 10% to R21,1 billion

H1 2024 Results Presentation

View the online version and select download options

Aspen concludes two significant agreements with Sandoz for China and Europe

Durban, South Africa – JSE-listed Aspen Pharmacare Holdings Limited, a global multinational specialty pharmaceutical company, has announced that Aspen Global Incorporated (“AGI”), its wholly owned subsidiary incorporated in Mauritius, has concluded two interdependent agreements with Sandoz AG (“Sandoz”) concerning the acquisition of Sandoz’s Chinese business and the disposal to Sandoz of four anaesthetic products in… Continue reading Aspen concludes two significant agreements with Sandoz for China and Europe

Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility

Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility Durban, South Africa – Aspen is pleased to announce further details on one of the contract manufacturing agreements mentioned in its recent announcement of financial results for the year ended 30 June 2023… Continue reading Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility

Aspen revenue exceeds R40 billion with accelerated medium-term growth anticipated

Stephen Saad, Aspen Group Chief Executive

Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported a strong performance for the year ended 30 June 2023. SALIENT HIGHLIGHTS Revenue grew by 5% (-3% in constant exchange rate (“CER”)) to R40 709 million (FY2022: R38 606) Normalised EBITDA rose by 1% (-6% in CER) to R11… Continue reading Aspen revenue exceeds R40 billion with accelerated medium-term growth anticipated

Our Purpose

Find out more
To improve the health and quality of life of patients.

Our Vision

Find out more
To deliver value to all our stakeholders as a responsible corporate citizen that provides high-quality, affordable medicines globally.

Our Values

Find out more
Define the foundation on which Aspen has been built. These are the values we share as we work together toward achieving the vision of the Group.
aspen-holdings-logo-white-img

Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912

Medical Careline (South Africa) 0800 118 088

Facebook-f Twitter-square Instagram Linkedin

About Aspen

We Care

Careers

Contact Us

ASPEN PHARMACARE HOLDINGS LTD:
Switchboard: +27 31 580-8600

Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
South Africa

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.